BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34530929)

  • 1. The intracellular milieu of Parkinson's disease patient brain cells modulates alpha-synuclein protein aggregation.
    Gustavsson N; Savchenko E; Klementieva O; Roybon L
    Acta Neuropathol Commun; 2021 Sep; 9(1):153. PubMed ID: 34530929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
    Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
    Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of Alpha Synuclein and Microtubule Organization Is Linked to Impaired Neuritic Integrity in Parkinson's Patient-Derived Neuronal Cells.
    Seebauer L; Schneider Y; Drobny A; Plötz S; Koudelka T; Tholey A; Prots I; Winner B; Zunke F; Winkler J; Xiang W
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
    Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
    Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
    Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
    Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
    J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
    Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats.
    Van Den Berge N; Ferreira N; Gram H; Mikkelsen TW; Alstrup AKO; Casadei N; Tsung-Pin P; Riess O; Nyengaard JR; Tamgüney G; Jensen PH; Borghammer P
    Acta Neuropathol; 2019 Oct; 138(4):535-550. PubMed ID: 31254094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.
    Tanudjojo B; Shaikh SS; Fenyi A; Bousset L; Agarwal D; Marsh J; Zois C; Heman-Ackah S; Fischer R; Sims D; Melki R; Tofaris GK
    Nat Commun; 2021 Jun; 12(1):3817. PubMed ID: 34155194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
    Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
    Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates.
    Rostami J; Mothes T; Kolahdouzan M; Eriksson O; Moslem M; Bergström J; Ingelsson M; O'Callaghan P; Healy LM; Falk A; Erlandsson A
    J Neuroinflammation; 2021 Jun; 18(1):124. PubMed ID: 34082772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible Alpha-Synuclein Expression Affects Human Neural Stem Cells' Behavior.
    Zasso J; Ahmed M; Cutarelli A; Conti L
    Stem Cells Dev; 2018 Jul; 27(14):985-994. PubMed ID: 29669468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
    He Y; Yu Z; Chen S
    ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
    Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
    Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
    Cole TA; Zhao H; Collier TJ; Sandoval I; Sortwell CE; Steece-Collier K; Daley BF; Booms A; Lipton J; Welch M; Berman M; Jandreski L; Graham D; Weihofen A; Celano S; Schulz E; Cole-Strauss A; Luna E; Quach D; Mohan A; Bennett CF; Swayze EE; Kordasiewicz HB; Luk KC; Paumier KL
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33682798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
    Imaizumi Y; Okada Y; Akamatsu W; Koike M; Kuzumaki N; Hayakawa H; Nihira T; Kobayashi T; Ohyama M; Sato S; Takanashi M; Funayama M; Hirayama A; Soga T; Hishiki T; Suematsu M; Yagi T; Ito D; Kosakai A; Hayashi K; Shouji M; Nakanishi A; Suzuki N; Mizuno Y; Mizushima N; Amagai M; Uchiyama Y; Mochizuki H; Hattori N; Okano H
    Mol Brain; 2012 Oct; 5():35. PubMed ID: 23039195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.